Objective To explore the clinical efficacy and safety of oxaliplatin combined with thymosin in the treatment of lung cancer with malignant pleural effusion. Methods Sixty-eight patients with lung cancer complicated with malignant pleural effusion（MPE） in our hospital from February 2015 to September 2017 were selected as the research subjects.The patients were divided into study group and control group according to different treatment regimens,34 cases in each group.The study group was treated with thymosin on the basis of oxaliplatin,and the control group was treated with oxaliplatin alone,and the effect of two groups,the incidence of ADR after medication and the improvement of KPS score were compared. Results The CR,PR,NC and PD of the study group and the control group had statistical differences（χ~2=21.095,P=0.000,χ~2=4.417,P=0.036,χ~2=8.609,P=0.003,χ~2=6.058,P=0.014）.The incidence of adverse reactions in the study group was 2.94%,significantly lower than 11.76% in the control group（χ~2=5.712,P=0.017）.The improvement of KPS score in the study group was significantly better than that of the control group（χ~2=8.854,P=0.003,χ~2=4.654,P=0.031,χ~2=6.058, P=0.014）,and the comparison between the groups was statistically significant. Conclusion Compared with a single drug,the combined treatment of thymosin on the basis of oxaliplatin is more effective.It can promote the decline of various clinical symptoms and signs,further improve the therapeutic effect,and have no obvious side effects.It is beneficial to improve the quality of life and improve the prognosis, which has high clinical value.
China medicine and pharmacy
Malignant pleural effusion